Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1980 May;65(5):1238–1242. doi: 10.1172/JCI109779

Antibody to the Rheumatoid Arthritis Nuclear Antigen

ITS RELATIONSHIP TO IN VIVO EPSTEIN-BARR VIRUS INFECTION

Michael A Catalano 1,2,3, Dennis A Carson 1,2,3, James C Niederman 1,2,3, Paul Feorino 1,2,3, John H Vaughan 1,2,3
PMCID: PMC371458  PMID: 6245108

Abstract

Most patients with seropositive rheumatoid arthritis, and a variable but lesser percentage of normal subjects, have precipitating antibodies to a nuclear antigen, rheumatoid arthritis nuclear antigen, present in Epstein-Barr virus-infected human B lymphoblastoid cells. We have used a sensitive indirect immunofluorescence assay for antibody to rheumatoid arthritis nuclear antigen in a study of patients with infectious mononucleosis and healthy control subjects. Of 110 sera from normal, college-age cadets, 58 were from individuals without prior Epstein-Barr virus infection, as indicated by the lack of antibody to viral capsid antigen. All of these also lacked activity to rheumatoid arthritis nuclear antigen. 52 sera were positive for antibody to viral capsid antigen, and antibody to rheumatoid arthritis nuclear antigen was present in 26 (50%) of these. In 67 sequential sera from 11 college-age students with infectious mononucleosis who became positive for antibody to rheumatoid arthritis nuclear antigen, only 2 were positive during the 1 mo. Thereafter the incidence and titers increased progressively through the 1st yr after infection. This time-course resembled that for the development of antibody to Epstein-Barr nuclear antigen, another transformation antigen in Epstein-Barr virus-infected B lymphocytes. The development of positivity for both was much later than that of antibody to the structural viral capsid antigen, which in the current study was always positive by 1 wk. Thus, antibody to rheumatoid arthritis nuclear antigen is present in a large proportion of normal individuals and can now be clearly ascribed, from both in vivo and in vitro studies, to prior infection with Epstein-Barr virus.

Full text

PDF
1238

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alspaugh M. A., Jensen F. C., Rabin H., Tan E. M. Lymphocytes transformed by Epstein-Barr virus. Induction of nuclear antigen reactive with antibody in rheumatoid arthritis. J Exp Med. 1978 Apr 1;147(4):1018–1027. doi: 10.1084/jem.147.4.1018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alspaugh M. A., Tan E. M. Antibodies to cellular antigens in Sjögren's syndrome. J Clin Invest. 1975 May;55(5):1067–1073. doi: 10.1172/JCI108007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Aslpaugh M. A., Tan E. M. Serum antibody in rheumatoid arthritis reactive with a cell-associated antigen. Demonstration by precipitation and immunofluorescence. Arthritis Rheum. 1976 Jul-Aug;19(4):711–719. doi: 10.1002/1529-0131(197607/08)19:4<711::aid-art1780190409>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  4. Baron D., Strominger J. L. Partial purification and properties of the Epstein-Barr virus-associated nuclear antigen. J Biol Chem. 1978 Apr 25;253(8):2875–2881. [PubMed] [Google Scholar]
  5. Catalano M. A., Carson D. A., Slovin S. F., Richman D. D., Vaughan J. H. Antibodies to Epstein-Barr virus-determined antigens in normal subjects and in patients with seropositive rheumatoid arthritis. Proc Natl Acad Sci U S A. 1979 Nov;76(11):5825–5828. doi: 10.1073/pnas.76.11.5825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. DAVIDSOHN I., LEE C. L. SEROLOGIC DIAGNOSIS OF INFECTIOUS MONONUCLEOSIS. A COMPARATIVE STUDY OF FIVE TESTS. Am J Clin Pathol. 1964 Feb;41:115–125. doi: 10.1093/ajcp/41.2.115. [DOI] [PubMed] [Google Scholar]
  7. Henie G., Henle W., Horwitz C. A. Antibodies to Epstein-Barr virus-associated nuclear antigen in infectious mononucleosis. J Infect Dis. 1974 Sep;130(3):231–239. doi: 10.1093/infdis/130.3.231. [DOI] [PubMed] [Google Scholar]
  8. Henle G., Henle W. Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol. 1966 Mar;91(3):1248–1256. doi: 10.1128/jb.91.3.1248-1256.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kaplan J., Shope T. C., Peterson W. D., Jr Epstein-barr virus-negative human malignant T-cell lines. J Exp Med. 1974 May 1;139(5):1070–1076. doi: 10.1084/jem.139.5.1070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lerner R. A., Hodge L. D. Gene expression in synchronized lymphocytes: studies on the control of synthesis of immunoglobulin polypeptides. J Cell Physiol. 1971 Apr;77(2):265–276. doi: 10.1002/jcp.1040770215. [DOI] [PubMed] [Google Scholar]
  11. Niederman J. C., McCollum R. W., Henle G., Henle W. Infectious mononucleosis. Clinical manifestations in relation to EB virus antibodies. JAMA. 1968 Jan 15;203(3):205–209. doi: 10.1001/jama.203.3.205. [DOI] [PubMed] [Google Scholar]
  12. Reedman B. M., Klein G. Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer. 1973 May;11(3):499–520. doi: 10.1002/ijc.2910110302. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES